PL2595485T3 - Sposoby zastosowania pochodnych amidów cyklicznych w leczeniu zaburzeń mediowanych przez receptor sigma - Google Patents
Sposoby zastosowania pochodnych amidów cyklicznych w leczeniu zaburzeń mediowanych przez receptor sigmaInfo
- Publication number
- PL2595485T3 PL2595485T3 PL11810350T PL11810350T PL2595485T3 PL 2595485 T3 PL2595485 T3 PL 2595485T3 PL 11810350 T PL11810350 T PL 11810350T PL 11810350 T PL11810350 T PL 11810350T PL 2595485 T3 PL2595485 T3 PL 2595485T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- amide derivatives
- mediated disorders
- cyclic amide
- sigma receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Agronomy & Crop Science (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36608010P | 2010-07-20 | 2010-07-20 | |
| PCT/US2011/044698 WO2012012543A1 (en) | 2010-07-20 | 2011-07-20 | Methods of use cyclic amide derivatives to treat sigma receptor-mediated disorders |
| EP11810350.6A EP2595485B1 (en) | 2010-07-20 | 2011-07-20 | Methods of use cyclic amide derivatives to treat sigma receptor-mediated disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2595485T3 true PL2595485T3 (pl) | 2022-06-20 |
Family
ID=45497167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11810350T PL2595485T3 (pl) | 2010-07-20 | 2011-07-20 | Sposoby zastosowania pochodnych amidów cyklicznych w leczeniu zaburzeń mediowanych przez receptor sigma |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20130274290A1 (pl) |
| EP (2) | EP4070794A3 (pl) |
| JP (3) | JP2013531073A (pl) |
| KR (1) | KR101867634B1 (pl) |
| CN (2) | CN107007603A (pl) |
| BR (1) | BR112013001302A2 (pl) |
| CA (2) | CA2805904C (pl) |
| DK (1) | DK2595485T3 (pl) |
| ES (1) | ES2914120T3 (pl) |
| HU (1) | HUE058736T2 (pl) |
| PL (1) | PL2595485T3 (pl) |
| PT (1) | PT2595485T (pl) |
| RU (2) | RU2746871C2 (pl) |
| TW (1) | TWI520949B (pl) |
| WO (1) | WO2012012543A1 (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8937900B2 (en) | 2010-07-20 | 2015-01-20 | Qualcomm Incorporated | Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies |
| WO2015191554A1 (en) * | 2014-06-09 | 2015-12-17 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
| MY185516A (en) * | 2014-12-02 | 2021-05-19 | Mitsubishi Tanabe Pharma Corp | Compositions and methods for treating schizophrenia |
| SG11201810358YA (en) * | 2016-05-25 | 2018-12-28 | Mitsubishi Tanabe Pharma Corp | Compositions and methods for treating negative symptoms in non-schizophrenic patients |
| CN111511353A (zh) | 2017-06-21 | 2020-08-07 | 田边三菱制药株式会社 | 耐胃液的控释口服剂型 |
| BR112021002654A2 (pt) | 2018-08-21 | 2021-05-04 | Minerva Neurosciences, Inc. | uso de roluperidona para tratar sintomas e distúrbios negativos, aumentar a neuroplasticidade e promover neuroproteção |
| EP4153209A1 (en) | 2020-05-20 | 2023-03-29 | The Board of Trustees of the University of Illinois | Method for treating lysosomal storage diseases with histatin peptides |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA908641B (en) * | 1989-10-27 | 1992-06-24 | Du Pont | (n-phthalimidoalkyl)piperidines |
| IE903857A1 (en) * | 1989-10-27 | 1991-05-08 | Du Pont Merck Pharma | (N-Phthalimidoalkyl)Piperidines |
| DK0637306T3 (da) * | 1992-04-23 | 2001-07-30 | Merrell Pharma Inc | 4-Imidomethyl-1-[2'-phenyl-2'-oxoethyl]-piperidiner som serotonin-5HT2-antagonister, deres fremstilling og anvendelse til terapi |
| IL151533A0 (en) * | 2000-02-29 | 2003-04-10 | Mitsubishi Pharma Corp | Novel cyclic amide derivatives |
| TW200817400A (en) * | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
-
2011
- 2011-07-20 WO PCT/US2011/044698 patent/WO2012012543A1/en active Application Filing
- 2011-07-20 CN CN201611063838.0A patent/CN107007603A/zh active Pending
- 2011-07-20 JP JP2013520841A patent/JP2013531073A/ja active Pending
- 2011-07-20 KR KR1020137004218A patent/KR101867634B1/ko active IP Right Grant
- 2011-07-20 CA CA2805904A patent/CA2805904C/en active Active
- 2011-07-20 CN CN2011800450188A patent/CN103108548A/zh active Pending
- 2011-07-20 EP EP22162273.1A patent/EP4070794A3/en active Pending
- 2011-07-20 US US13/810,775 patent/US20130274290A1/en not_active Abandoned
- 2011-07-20 PT PT118103506T patent/PT2595485T/pt unknown
- 2011-07-20 HU HUE11810350A patent/HUE058736T2/hu unknown
- 2011-07-20 CA CA3154027A patent/CA3154027A1/en active Pending
- 2011-07-20 RU RU2017105262A patent/RU2746871C2/ru active
- 2011-07-20 DK DK11810350.6T patent/DK2595485T3/da active
- 2011-07-20 ES ES11810350T patent/ES2914120T3/es active Active
- 2011-07-20 PL PL11810350T patent/PL2595485T3/pl unknown
- 2011-07-20 EP EP11810350.6A patent/EP2595485B1/en active Active
- 2011-07-20 TW TW100125662A patent/TWI520949B/zh active
- 2011-07-20 RU RU2013107378A patent/RU2613201C2/ru active
- 2011-07-20 BR BR112013001302A patent/BR112013001302A2/pt not_active Application Discontinuation
-
2016
- 2016-05-24 US US15/163,385 patent/US20160354357A1/en not_active Abandoned
- 2016-07-07 JP JP2016135208A patent/JP2016199578A/ja active Pending
-
2017
- 2017-11-22 JP JP2017225061A patent/JP6419294B2/ja active Active
-
2020
- 2020-06-29 US US16/914,862 patent/US20210106573A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP6419294B2 (ja) | 2018-11-07 |
| ES2914120T3 (es) | 2022-06-07 |
| RU2017105262A3 (pl) | 2019-01-18 |
| RU2013107378A (ru) | 2014-08-27 |
| KR101867634B1 (ko) | 2018-06-15 |
| BR112013001302A2 (pt) | 2017-07-04 |
| EP2595485A4 (en) | 2014-04-23 |
| TW201211022A (en) | 2012-03-16 |
| US20210106573A1 (en) | 2021-04-15 |
| CA3154027A1 (en) | 2012-01-26 |
| TWI520949B (zh) | 2016-02-11 |
| HUE058736T2 (hu) | 2022-09-28 |
| RU2613201C2 (ru) | 2017-03-15 |
| RU2746871C2 (ru) | 2021-04-21 |
| US20130274290A1 (en) | 2013-10-17 |
| PT2595485T (pt) | 2022-05-30 |
| JP2013531073A (ja) | 2013-08-01 |
| RU2017105262A (ru) | 2019-01-18 |
| CA2805904C (en) | 2022-06-21 |
| EP4070794A2 (en) | 2022-10-12 |
| JP2018065829A (ja) | 2018-04-26 |
| DK2595485T3 (da) | 2022-05-30 |
| CN103108548A (zh) | 2013-05-15 |
| JP2016199578A (ja) | 2016-12-01 |
| EP2595485A1 (en) | 2013-05-29 |
| KR20130129906A (ko) | 2013-11-29 |
| CN107007603A (zh) | 2017-08-04 |
| WO2012012543A1 (en) | 2012-01-26 |
| US20160354357A1 (en) | 2016-12-08 |
| CA2805904A1 (en) | 2012-01-26 |
| EP4070794A3 (en) | 2023-01-18 |
| EP2595485B1 (en) | 2022-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL226401A0 (en) | Methods for treating disorders related to @fgfBA | |
| IL221476A0 (en) | Methods and compositions to treat hemorrhagic conditions of the brain | |
| EP2827869A4 (en) | COMPOSITIONS AND METHODS FOR IMPROVING THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ITS ANALOGUES INCLUDING MESOINDIGO | |
| EP2552433A4 (en) | COMPOSITIONS AND METHODS OF TREATING SOMATOSENSORY DISEASES | |
| HK1258530A1 (zh) | Serpina 1 sirnas:物質的組合物和治療方法 | |
| IL217901A0 (en) | Treatment of bdnf-related disorders using laquninimod | |
| ZA201205829B (en) | Treatment of respiratory disorders | |
| EP2571360A4 (en) | METHODS AND FORMULATIONS FOR THE TREATMENT BY OXYTOCINE OF DISORDERS RELATED TO THE USE OF TOXIC SUBSTANCES, PSYCHIATRIC DISORDERS AND OTHER DISORDERS | |
| HUE058736T2 (hu) | Gyûrûs amidszármazékok alkalmazási módszerei szigma receptor közvetített rendellenességek kezelésére | |
| ZA201405263B (en) | Cyclic amide derivatives as inhibitors of 11 - beta - hydroxysteroid dehydrogenase and uses thereof | |
| GB201202773D0 (en) | Compositions for treatment of skin disorders | |
| IL256026A (en) | Treatment methods | |
| IL225896A0 (en) | Treatment of mecp-2 related disorders | |
| EP2473171A4 (en) | METHODS OF TREATING MITOCHONDRIAL DISORDERS USING METALLOPORPHYRINS | |
| PL2694532T3 (pl) | Pochodne aureobasidin i sposoby syntezy | |
| EP2672963A4 (en) | METHOD FOR THE TREATMENT OF MELANOMA | |
| PL2595484T3 (pl) | Zastosowanie cyklicznych pochodnych amidowych do leczenia zaburzeń snu | |
| HK1201518A1 (en) | Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives | |
| ZA201108571B (en) | Use of pufas to treat nerve damage | |
| EP2600716A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES | |
| GB201003124D0 (en) | Treatment of oxidative stress disorders | |
| GB201119458D0 (en) | Compositions for treatment of sleep disorders | |
| GB201001912D0 (en) | Treatment of respiratory disorders |